GET A SECOND MEDICAL OPINION WITHIN 48 HOURS!
🧬 PRRT THERAPY IN TURKEY (PEPTIDE RECEPTOR RADIONUCLIDE THERAPY)
Advanced Targeted Treatment for Neuroendocrine Tumors (NETs)
Peptide Receptor Radionuclide Therapy (PRRT) is a highly specialized form of nuclear medicine used to treat neuroendocrine tumors (NETs) — rare cancers that often spread silently throughout the body.
This treatment delivers targeted radiation directly to tumor cells, offering new hope to patients who no longer respond to conventional therapies.
At Medicine Park International, we help patients from Romania, Europe, and beyond access world-class PRRT therapy centers in Turkey, where cutting-edge medicine meets personalized care.
💡 What Is PRRT (Peptide Receptor Radionuclide Therapy)?
PRRT is a molecularly targeted treatment that uses a radiolabeled molecule — a combination of:
A peptide that binds specifically to receptors on tumor cells (like somatostatin receptors), and
A radioactive isotope that delivers radiation precisely to those cells.
When injected into the bloodstream, this compound attaches only to cancer cells, destroying them from within while minimizing damage to healthy tissues.
The most common PRRT radiopharmaceuticals include:
Lutetium-177 (Lu-177 DOTATATE)
Yttrium-90 (Y-90 DOTATOC)
These agents have been proven effective for neuroendocrine tumors originating in the pancreas, intestine, and lungs.
⚕️ CONDITIONS TREATED WITH PRRT
PRRT is primarily used to treat neuroendocrine tumors (NETs) that express somatostatin receptors and are inoperable, metastatic, or resistant to other treatments.
Common indications include:
Pancreatic neuroendocrine tumors (pNETs)
Gastrointestinal (midgut) NETs
Bronchial (lung) NETs
Carcinoid tumors
Recurrent or progressive NETs after chemotherapy or surgery
This therapy improves both tumor control and quality of life, with fewer side effects than traditional chemotherapy.
🧬 HOW PRRT WORKS
Preparation Phase
Diagnostic imaging (like PET-CT with Ga-68 DOTATATE) confirms that the tumors have somatostatin receptors suitable for PRRT.
Blood and kidney function tests are performed.Treatment Administration
The radiopharmaceutical (Lu-177 DOTATATE or Y-90 DOTATOC) is injected intravenously over about 30–40 minutes.
The therapy is usually given in 3–4 cycles, spaced 8–12 weeks apart.Protection and Monitoring
Amino acid infusions are provided to protect the kidneys.
Vital signs and radiation levels are monitored closely.Follow-Up
After each cycle, blood tests and imaging are done to assess response and adjust the next dose if necessary.
The procedure is well-tolerated, typically requiring a 1–2 day hospital stay per cycle.
🌍 WHY CHOOSE TURKEY FOR PRRT THERAPY?
Turkey is one of the few countries in Europe where PRRT is widely available at affordable prices, performed in JCI-accredited hospitals with state-of-the-art nuclear medicine departments.
Advantages:
🧪 Highly experienced nuclear medicine specialists
🧬 Access to Lu-177 and Y-90 therapies approved internationally
🏥 Modern isolation rooms and radiation safety protocols
🕒 Short waiting times — fast appointment scheduling
💰 Significant cost savings compared to Western Europe
✈️ Complete coordination by Medicine Park International
Our team ensures that international patients receive world-class care from consultation to follow-up.
✈️ HOW MEDICINE PARK INTERNATIONAL HELPS YOU
We make advanced cancer care abroad simple and stress-free.
Free medical evaluation — send your reports for specialist review.
Eligibility check — we confirm receptor positivity and treatment suitability.
Treatment plan & quotation — transparent pricing and timeline for PRRT cycles.
Travel organization — flights, accommodation, and transfers included.
On-site medical assistance — interpreter and coordinator present during treatment.
Continuous follow-up — we stay in touch after each therapy cycle.
Your journey to advanced cancer care starts here — with professional coordination and compassionate support.
